Note: Due to inclement weather, this event has been postponed. It will now take place March 22 at 10 am—11:30 am, and will be located at the Washington Office on Latin America (1666 Connecticut Ave., NW | Washington, D.C. 20009). There will also be a free livestream of the event here. Our apologies for any inconveniences this delay may have caused.
As the first country to legalize and regulate non-medical cannabis, the case of Uruguay holds important lessons for other jurisdictions that may consider regulatory approaches to cannabis instead of persisting with prohibition. The stated goals of the December 2013 law regulating cannabis in Uruguay were to reduce violence stemming from drug trafficking, promote public health, and eliminate the contradictions in laws regarding cannabis access and use. Uruguay’s leaders, mindful of domestic and international concerns, have taken a deliberately strict approach to regulating cannabis. Consumers must choose only one of the three forms of legal access to cannabis—homegrowing, clubs, or commercial purchase—and must register with the Institute for the Regulation and Control of Cannabis (IRCCA). Only two companies are currently licensed to produce cannabis for sale, the price is fixed, there are weekly and monthly purchase limits, and sales to tourists are not permitted. Commercial sales through pharmacies began in July 2017 but have been hindered by supply problems and by curtailed access to financial services—a constraint that applies to U.S. cannabis dispensaries as well—pushing Uruguayan authorities to consider creating new, cash-only cannabis sales outlets.
On March 21, the Center for Effective Public Management at Brookings and the Washington Office on Latin America (WOLA) released a paper examining Uruguay’s progress in implementing its pioneering cannabis law. The following day, March 22, Brookings’ John Hudak and WOLA’s John Walsh, two of the paper’s authors, were joined by a panel of experts to discuss the challenges and opportunities Uruguay faces five years after legalization at the D.C. offices of WOLA.
After the session, speakers took audience questions.
Owner - Farmacia La Cabina
Executive Director - Instituto de Regulación y Control del Cannabis (IRCCA)
Director for Drug Policy and the Andes - Washington Office on Latin America
To subscribe or manage your subscriptions to our top event topic lists, please visit our event topics page.
The Duque government’s drug policy in Colombia is taking on a progressively ominous and counterproductive direction. It threatens to undermine the incomplete and struggling peace process, misdirect law enforcement resources, augment the alienation of coca farmers from the state and undermine human rights and drug users’ access to health services in Colombia. With their emphasis on criminalization of even drug possession for personal use and forced eradication, the announced policies clearly cater to the Trump administration’s doctrinaire and discredited drug policy preferences that harken back to the 1980s. But without sustainable livelihoods already in place, forced eradication will not sustainably reduce coca cultivation and cocaine production. The dominance of zero-coca thinking in Colombia whereby a community has to eradicate all coca first before it starts receiving even meager assistance from the state never produced positive results in Colombia.